Older data but interesting ..MS summary, page-11

Here’s the thing !
”Buy on Rumour Sell on Fact”
Reason why The sp will continue upwards:
1) EAP approval validates the drug( Sarepta and others failed to impress EMA)
2) End points are the same @25mg per week as the European DMD trial
3) Only 1 trial away from Commercialisation for a $4 billion market
4)So from Monday ( hopefully the EAP approval)
. we will soon learn of the $ Funding ? CR. Retail..
. Pharma license ….Large Fund … etc
5)Anp will have sufficient $Funds to move on other indications
6) Blood plasma data to be released in a Medical Journal
7)Large number of indications to be licensed out to whoever $$ Far to many for Anp to go alone.( Respiratory, Neurodegenerative, Neuromuscular,Fibrosis etc.

Finance will be the least of our worries within 6 months..
So while the 12 month study continues in Europe
Multiple announcements will follow …$$$

Why settle for 60c when by Christmas it will be $1 by mid next year it should be $2 and so on..

On a positive EMA approval on Monday we start our journey like FMG.
Atl1102 derisked ..




.